Table 4.
Atorvastatin and atorvastatin metabolite pharmacokinetics by ABCB1 diplotype group.
| ABCB1 Diplotype | Pharmacokinetic Parameters |
||
|---|---|---|---|
| Cmax (ng/ml) | AUCtau (ng*h/ml) | T1/2 (h) | |
| Atorvastatin | |||
| CGC/CGC | 8.6 ± 6.2 | 44.4 ± 28.0 | 5.7 ± 1.2 |
| CGC/TTT | 7.5 ± 7.6 | 35.4 ± 35.6 | 6.9 ± 2.0 |
| TTT/TTT | 10.6 ± 7.4 | 49.0 ± 37.1 | 6.4 ± 2.1 |
| P value, between diplotype groups | 0.43 | 0.29 | 0.55 |
|
| |||
| Atorvastatin lactone | |||
| CGC/CGC | 11.0 ± 11.9 | 87.3 ± 69.3 | 7.0 ± 2.5 |
| CGC/TTT | 7.4 ± 4.7 | 69.8 ± 54.7 | 6.7 ± 2.3 |
| TTT/TTT | 13.8 ± 11.2 | 101.0 ± 64.2 | 9.2 ± 6.0 |
| P value, between diplotype groups | 0.23 | 0.35 | 0.66 |
|
| |||
| 2-hydroxyatorvastatin | |||
| CGC/CGC | 5.5 ± 3.4 | 43.2 ± 21.6 | 6.3 ± 2.7 |
| CGC/TTT | 5.1 ± 4.1 | 45.0 ± 38.7 | 7.5 ± 3.0 |
| TTT/TTT | 4.5 ± 2.3 | 38.6 ± 19.5 | 7.0 ± 1.5 |
| P value, between diplotype groups | 0.93 | 0.93 | 0.32 |
|
| |||
| 2-hydroxyatorvastatin lactone | |||
| CGC/CGC | 4.4 ± 3.5 | 37.3 ± 22.5 | 6.8 ± 1.8 |
| CGC/TTT | 4.1 ± 3.0 | 42.6 ± 31.1 | 7.8 ± 4.2 |
| TTT/TTT | 3.9 ± 1.9 | 38.5 ± 19.3 | 9.9 ± 8.5 |
| P value, between diplotype groups | 0.98 | 0.96 | 0.92 |
|
| |||
| 4-hydroxyatorvastatin | |||
| CGC/CGC | 0.48 ± 0.61 | 4.6 ± 4.6 | 14.2 ± 4.3 |
| CGC/TTT | 0.25 ± 0.14 | 3.2 ± 1.6 | 19.3 ± 12.9 |
| TTT/TTT | 0.39 ± 0.34 | 5.1 ± 4.5 | 12.6 ± 5.2 |
| P value, between diplotype groups | 0.61 | 0.61 | 0.29 |
|
| |||
| 4-hydroxyatorvastatin lactone | |||
| CGC/CGC | 0.84 ± 0.11 | 9.1 ± 10.2 | 10.5 ± 5.5 |
| CGC/TTT | 0.7 ± 0.43 | 7.2 ± 4.0 | 12.8 ± 4.3 |
| TTT/TTT | 0.91 ± 0.64 | 10.4 ± 7.0 | 14.5 ± 8.8 |
| P value, between diplotype groups | 0.63 | 0.46 | 0.29 |
ABCB1 CGC/CGC, n=9; ABCB1 CGC/TTT, n=10; ABCB1 TTT/TTT, n=10. Data are expressed as arithmetic mean ± standard deviation.